Clinical Trial to Assess Bemiparin Pharmacokinetics at Therapeutic (115 IU/kg) and Prophylactic Doses (3500 IU) Administered Subcutaneously in Single or Multiple Doses in Renal Insufficiency and in the Elderly.
Phase of Trial: Phase I
Latest Information Update: 17 Mar 2011
At a glance
- Drugs Bemiparin sodium (Primary)
- Indications Thrombosis
- Focus Pharmacokinetics
- Sponsors Rovi
- 17 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 12 Feb 2007 Status change